Structural Models for Substrates and Inhibitors of Cytochrome P450 Enzymes

  • T. Wolff
  • G. Strobl
  • H. Greim
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 105)

Abstract

Although a large number of drugs, chemicals, and endogenous compounds are known as substrates or inhibitors of microsomal cytochrome P450 enzymes, systematic attempts to explore substrate and inhibitor specificity of individual cytochrome P450 species have been occasional. An improved understanding of the specificity of individual cytochrome P450 enzymes, however, is desirable for several reasons. First, animal species differ from each other and from humans with respect to their patterns of cytochrome P450 enzymes involved in detoxication and bioactivation of cytotoxic and genotoxic chemicals. More knowledge of the specificity of these enzymes facilitates the explanation of species differences in metabolism and facilitates the design of chemical toxicity studies. Furthermore, reliable substrate models offer the opportunity to predict whether a drug is likely to be a substrate of a particular cytochrome P450 enzyme and thus whether its plasma concentration and, consequently, its therapeutic effects may be subjected to interindividual variations of the activity of this enzyme. Likewise, more knowledge about structural features of compounds inhibitory for cytochrome P450 enzymes is required, to evaluate whether one drug may be inhibitory for the metabolism of one or more other drugs.

Keywords

Polycyclic Aromatic Hydrocarbon Pyrene Aniline Metoprolol Anthracene 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cohen GM, Mannering GJ (1973) Involvement of a hydrophobic site in the inhibition of the microsomal p-hydroxylation of aniline by alcohols. Mol Pharmacol 9: 383–397PubMedGoogle Scholar
  2. Eichelbaum M, Gross AS (1990) The genetic polymorphism of debrisoquine/ sparteine metabolism-clinical aspects. Pharmacol Ther 46: 377–394PubMedCrossRefGoogle Scholar
  3. Ferenzy GG, Morris GM (1989) The active site of cytochrome P-450 nifedipine oxidase: a model-building study. J Mol Graphics 7: 206–211CrossRefGoogle Scholar
  4. Fonne-Pfister R, Meyer UA (1988) Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism. Biochem Pharmacol 37: 3829–3835PubMedCrossRefGoogle Scholar
  5. Hansch C (1971) Quantitative structure-activity relationships in drug design. In: Ariens EJ (ed) Drug design, vol 1. Academic, New York, pp 271–342Google Scholar
  6. Hansch C, Clayton JM (1973) Lipophilic character and biological activity of drugs: II. The parabolic case. J Pharm Sci 62: 1–21PubMedCrossRefGoogle Scholar
  7. Hansch C, Fujita T (1964) pair-analysis. A method for the correlation of biological activity and chemical structure. J Am Chem Soc 86: 1616–1626CrossRefGoogle Scholar
  8. Inaba T, Nakano M, Otton SV, Mahon WA, Kalow W (1984) A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenase. Can J Physiol Pharmacol 62: 860–862PubMedCrossRefGoogle Scholar
  9. Inaba T, Jurima M, Mahon WA, Kalow W (1985) In vitro inhibition studies of two isoenzymes of human liver cytochrome P-450. Drug Metab Dispos 13: 443–448PubMedGoogle Scholar
  10. Islam SA, Wolf CR, Lennard MS, Sternberg MJE (1991) A three-dimensional molecular template for substrates of human cytochrome P-450 involved in debrisoquine 4-hydroxylation. Carcinogenesis 12: 2211–2219PubMedCrossRefGoogle Scholar
  11. Jerina DM, Michaud DP, Feldmann RJ, Armstrong RN, Vyas KP, Thakker DR, Yagi H, Thomas PE, Ryan DE, Levin W (1982) Stereochemical modeling of the catalytic site of cytochrome P-450c. In: Sato R, Kato R (eds) Microsomes, drug oxidations, and drug toxicity. Japan Scientific Societies, Tokyo, pp 195–201Google Scholar
  12. Kellis JT, Vickery LE (1987) The active site of aromatase cytochrome P-450. J Biol Chem 262 18: 8840–8844PubMedGoogle Scholar
  13. Kronbach T, Dayer P, Meyer UA (1985) Debrisoquine(D)/sparteine (SP)-type polymorphism in drug oxidation: a model of the active site of the involved cytochrome P-450 isozyme. Experientia 41: 822Google Scholar
  14. Kronbach T, Mathys D, Gut J, Catin T, Meyer UA (1987) High performance liquid chromatographic assays for bufuralol l’-hydroxylase, debrisoquine 4- hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P450 isozymes of human liver. Anal Biochem 162: 24–32PubMedCrossRefGoogle Scholar
  15. Kubinyi H (1990) Quantitative structure-activity relationships (QSAR) and molecular modelling in cancer research. J Res Clin Oncol 116: 529–537CrossRefGoogle Scholar
  16. Laughton CA, Neidle S (1990) Inhibitors of the P-450 enzymes aromatase and lyase. Crystallographic and molecular modeling studies suggest structural features of pyridylacetic acid derivatives responsible for differences in enzyme inhibitory activity. J Med Chem 33: 3055–3060PubMedCrossRefGoogle Scholar
  17. Laughton CA, Neidle S, Zvelebil MJJM, Sternberg MJE (1990) A molecular model for the enzyme cytochrome P45017a, a major target for the chemotherapy of prostatic cancer. Biochem Biophys Res Commun 171: 1160–1167PubMedCrossRefGoogle Scholar
  18. Lewis DFV (1987) Quantitative structure-activity relationships in a series of alcohols exhibiting inhibition of cytochrome P-450 mediated aniline hydroxylation. Chem Biol Interact 62: 271–280PubMedCrossRefGoogle Scholar
  19. Lewis DFV, Ioannidis C, Parke DV (1987) Structural requirements for substrates of cytochromes P-450 and P-448. Chem Biol Interact 64: 39–60PubMedCrossRefGoogle Scholar
  20. Lu AYH, West SB (1980) Multiplicity of mammalian microsomal cytochromes P-450. Pharmacol Rev 31: 277–295Google Scholar
  21. Marshall GR (1987) Computer-aided drug design. Annu Rev Pharmacol Toxicol 27: 193–213PubMedCrossRefGoogle Scholar
  22. Miwa GT, Walsh JS, Lu AYH (1984) Kinetic isotope effects on cytochrome P-450-catalyzed oxidation reactions: the oxidative O-dealkylation of 7- ethoxycoumarin. J Biol Chem 259: 3000–3004PubMedGoogle Scholar
  23. Murray M (1989) Inhibition of drug metabolism by phenothiazine tranquilizers: quantitative structure-activity relationships and selective inhibition of cytochrome P-450 isoform-specific activities. Chem Res Toxicol 2: 240–246PubMedCrossRefGoogle Scholar
  24. Nelson DR, Strobel HW (1989) Secondary structure prediction of 52 membrane-bound cytochromes P450 shows a strong structural similarity to P450cam. Biochemistry 28: 656–660PubMedCrossRefGoogle Scholar
  25. Otton SV, Inaba T, Kalow W (1984) Competitive inhibition of sparteine oxidation in human liver by P-adrenoceptor antagonists and other cardiovascular drugs. Life Sci 34: 73–80PubMedCrossRefGoogle Scholar
  26. Poulos TL, Howard A J (1987) Crystal structures of metyrapone- and phenylimidazole-inhibited complexes of cytochrome P-450cam. Biochemistry 26: 8165–8174PubMedCrossRefGoogle Scholar
  27. Poulos TL, Finzel BC, Gunsalus IC, Wagner GC, Kraut JJ (1985) The 2.6-A crystal structure of Pseudomonas putida cytochrome P-450. J Biol Chem 260: 16122–16130PubMedGoogle Scholar
  28. Poulos TL, Finzel BC, Howard AJ (1986) Crystal structure of substrate-free Pseudomonas putida cytochrome P-450. Biochemistry 25: 5314–5322PubMedCrossRefGoogle Scholar
  29. Poulos TL, Finzel BC, Howard AJ (1987) High-resolution crystal structure of cytochrome P450cam. J Mol Biol 195: 687–700PubMedCrossRefGoogle Scholar
  30. Sabljic A, Protic-Sabljic M (1983) Quantitative structure-activity study on the mechanism of inhibition of microsomal p-hydroxylation of aniline by alcohols. Mol Pharmacol 23: 213–218PubMedGoogle Scholar
  31. Schwarze W, Jaeger J, Janig GR, Ruckpaul K (1988) Active site model of cytochrome P-450 LM2. Biochem Biophys Res Commun 150: 996–1005PubMedCrossRefGoogle Scholar
  32. Strobl GR, Wolff T (1992a) Structural models for inhibitors and substrates of cytochrome P-450 2D6 based on molecular modeling analysis. In: Archakov AI, Bachmanova (eds) Cytochrome P-450: structure and function, biotechnological and ecological aspects. INCO-TNC, Moscow, Russia, 1992, pp 736–738Google Scholar
  33. Strobl GR, von Kruedener S, Stoeckigt J, Guengerich FP, Wolff T (1992b) Development of a pharmacophor for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. J Med Chem 1993 (in press)Google Scholar
  34. Testa B (1981) Structural and electronic factors influencing the inhibition of aniline hydroxylation by alcohols and their binding to cytochrome P-450. Chem Biol Interact 34: 287–300PubMedCrossRefGoogle Scholar
  35. Tullman RH, Walsh JS, Miwa GT (1984) The stereochemistry of P-450 and P-448 catalyzed O-dealkylation of 7-ethoxycoumarin. Fed Proc 43: 346Google Scholar
  36. Verloop A, Hoogenstraaten W, Tipker J (1976) Development and applications of new steric substituent parameters in drug design. In: Ariens EJ (ed) Drug design, vol 7. Academic, New York, pp 165–207Google Scholar
  37. Wolff T, Distlerath LM, Worthington MT, Groopman JD, Hammons GJ, Kadlubar FF, Prough RA, Martin MV, Guengerich FP (1985) Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling. Cancer Res 45: 2116–2122PubMedGoogle Scholar
  38. Wolff T, Wanders H, Guengerich FP (1989) Organic solvents as modifiers of aldrin epoxidase in reconstituted monooxygenase systems and in microsomes. Biochem Pharmacol 38: 4217–4223PubMedCrossRefGoogle Scholar
  39. Wrighton SA, Thomas PE, Ryan DE, Levin W (1987) Purification and characterization of ethanol-inducible human hepatic cytochrome P-450 HLj. Arch Biochem Biophys 258: 292–297PubMedCrossRefGoogle Scholar
  40. Yagi H, Jerina DM (1982) Absolute configuration of the trans-9, 10-dihydrodiol metabolite of the carcinogen benzo[a]pyrene. J Am Chem Soc 104: 4026–4027CrossRefGoogle Scholar
  41. Yang SK, Mushtaq M, Chiu, PL (1985) Stereoselective metabolism and activation of polycyclic aromatic hydrocarbons. In: Harvey RG (ed) Polycyclic hydrocarbons and carcinogens. American Chemical Society, Washington, pp 19–34 (Series No 283 )CrossRefGoogle Scholar
  42. Zvelebil MJJM, Wolf CR, Sternberg MJE (1991) A predicted three-dimensional structure of human cytochrome P450: implications for substrate specificity. Protein Eng 4: 271–282PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • T. Wolff
  • G. Strobl
  • H. Greim

There are no affiliations available

Personalised recommendations